Skip to content
ClinCalc Pro
Menu
Reduced folate (active enantiomer of folinic acid)

Levofolinic acid (calcium levofolinate)

Brand names: Isovorin

Levofolinic acid (calcium levofolinate) is the active levo-isomer of folinic acid used to counteract the toxicity of folic acid antagonists such as methotrexate and to modulate fluorouracil therapy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a reduced folate that bypasses dihydrofolate reductase to replenish intracellular folate pools (folinic rescue) and stabilises the binding of fluorouracil's active metabolite to thymidylate synthase.

Prescribing in practice

  • When used as rescue after high-dose methotrexate, timely administration guided by methotrexate levels and renal function is critical to prevent serious toxicity.
  • It must not be used to treat pernicious or other vitamin B12-deficiency anaemias because it can mask the haematological response while neurological damage progresses.
  • Combined with fluorouracil it enhances both efficacy and toxicity, so fluorouracil-related adverse effects may require dose adjustment.

Monitoring

When used for methotrexate rescue, monitor methotrexate concentrations and renal function to determine the duration and intensity of folinic rescue.

Counselling the patient

  • This medicine protects healthy cells from the effects of your chemotherapy.
  • If used with fluorouracil, report severe diarrhoea, mouth soreness or signs of infection promptly.
  • Take or attend for doses exactly as scheduled, as timing is important.

Evidence & guidelines

Folinic acid rescue after high-dose methotrexate and folinic acid modulation of fluorouracil are long-established standards of care in oncology.

Reference: UKHCDO; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.